OMC
RLMD icon

Old Mission Capital’s Relmada Therapeutics RLMD Stock Holding History

Old Mission Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-45,099
Closed -$111K – 1526
2023
Q2 		$111K Buy
+45,099
New +$125K ﹤0.01% 1069

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Old Mission Capital's RLMD Position: Q3 2023 in Review

Old Mission Capital sold out of Relmada Therapeutics (RLMD) in Q3 2023, closing a stake of 45,099 shares — an estimated $111K sold.

Old Mission Capital first reported a position in RLMD in Q2 2023 and held it in 1 quarter. The position peaked at $111K in Q2 2023. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

  • Old Mission Capital reported no remaining Relmada Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Old Mission Capital sold 45,099 Relmada Therapeutics shares in Q3 2023, an estimated $111K.
  • Old Mission Capital first reported a position in Relmada Therapeutics in Q2 2023 and held it in 1 quarter.
  • Old Mission Capital's Relmada Therapeutics position peaked at $111K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on Old Mission Capital's 13F filing for Q3 2023, filed 15 Nov 2023.